Search results for "Drug effect"

showing 10 items of 70 documents

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

2006

International audience; Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that induces cancer cell death by apoptosis with some selectivity. TRAIL-induced apoptosis is mediated by the transmembrane receptors death receptor 4 (DR4) (also known as TRAIL-R1) and DR5 (TRAIL-R2). TRAIL can also bind decoy receptor 1 (DcR1) (TRAIL-R3) and DcR2 (TRAIL-R4) that fail to induce apoptosis since they lack and have a truncated cytoplasmic death domain, respectively. In addition, DcR1 and DcR2 inhibit DR4- and DR5-mediated, TRAIL-induced apoptosis and we demonstrate here that this occurs through distinct mechanisms. While DcR1 prevents the assembly of the…

MESH : Hela CellsMESH: Membrane GlycoproteinsMESH: Membrane MicrodomainsDecoy Receptor 1ApoptosisMESH : Membrane GlycoproteinsReceptors Tumor Necrosis FactorTNF-Related Apoptosis-Inducing LigandMESH : TNF-Related Apoptosis-Inducing LigandJurkat Cells0302 clinical medicineMESH : Tumor Necrosis Factor Decoy ReceptorsMESH: Jurkat CellsDecoy receptorsReceptorCells CulturedMESH : Jurkat CellsMESH : Tumor Necrosis Factor-alpha0303 health sciencesMembrane GlycoproteinsMESH : Protein BindingArticlesMESH : Tumor Necrosis Factor Receptor-Associated Peptides and ProteinsTumor Necrosis Factor Receptor-Associated Peptides and ProteinsCell biology030220 oncology & carcinogenesisCaspasesDeath-inducing signaling complexApoptosis/drug effects; Apoptosis Regulatory Proteins/antagonists & inhibitors; Apoptosis Regulatory Proteins/pharmacology; Caspases/metabolism; Cells Cultured; Death Domain Receptor Signaling Adaptor Proteins; Enzyme Activation/drug effects; GPI-Linked Proteins; HeLa Cells; Humans; Jurkat Cells; Membrane Glycoproteins/antagonists & inhibitors; Membrane Glycoproteins/pharmacology; Membrane Microdomains/drug effects; Protein Binding/drug effects; Receptors TNF-Related Apoptosis-Inducing Ligand; Receptors Tumor Necrosis Factor/metabolism; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor Receptor-Associated Peptides and Proteins/metabolism; Tumor Necrosis Factor-alpha/antagonists & inhibitors; Tumor Necrosis Factor-alpha/pharmacologyMESH : Apoptosis Regulatory ProteinsMESH: TNF-Related Apoptosis-Inducing LigandProtein BindingMESH: Cells CulturedDeath Domain Receptor Signaling Adaptor ProteinsMESH: Enzyme ActivationBiologyMESH: Tumor Necrosis Factor Receptor-Associated Peptides and ProteinsGPI-Linked Proteins03 medical and health sciencesMembrane MicrodomainsCell surface receptorMESH : Cells Cultured[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologyReceptors Tumor Necrosis Factor Member 10cHumansMESH: Protein Binding[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyMESH: Receptors TNF-Related Apoptosis-Inducing LigandMESH : Receptors TNF-Related Apoptosis-Inducing LigandMolecular Biology[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular Biology030304 developmental biologyDeath domainMESH: CaspasesMESH: HumansTumor Necrosis Factor-alphaMESH: Apoptosis Regulatory ProteinsMESH: ApoptosisMESH : HumansCell BiologyMESH: Receptors Tumor Necrosis FactorMESH: Tumor Necrosis Factor Decoy ReceptorsMESH : Receptors Tumor Necrosis FactorEnzyme ActivationMESH: Hela CellsReceptors TNF-Related Apoptosis-Inducing LigandTumor Necrosis Factor Decoy ReceptorsApoptosisMESH: Tumor Necrosis Factor-alphaMESH : Membrane MicrodomainsMESH : CaspasesApoptosis Regulatory ProteinsMESH : Enzyme ActivationMESH : ApoptosisMESH : Death Domain Receptor Signaling Adaptor ProteinsTumor Necrosis Factor Decoy ReceptorsHeLa CellsMESH: Death Domain Receptor Signaling Adaptor Proteins
researchProduct

A functional analysis of ACP-20, an adult-specific cuticular protein gene from the beetle Tenebrio. Role of an intronic sequence in transcriptional a…

2004

0962-1075 (Print) Comparative Study Journal Article Research Support, Non-U.S. Gov't; A gene encoding the adult cuticular protein ACP-20 was isolated in Tenebrio. It consists of three exons interspersed by two introns, intron 1 interrupting the signal peptide. To understand the regulatory mechanisms of ACP-20 expression, ACP-20 promoter-luciferase reporter gene constructs were transfected into cultured pharate adult wing epidermis. Transfection assays needed the presence of 20-hydroxyecdysone, confirming that ACP-20 is up-regulated by ecdysteroids. Analysis of 5' deletion constructs revealed that three regions are necessary for high levels of transcription. Interaction experiments between i…

MESH : Molecular Sequence Data[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionMESH : Genes Reporter/physiologyMESH : Transcriptional Activation/geneticsMESH : Introns/geneticsPromoter Regions (Genetics)/drug effects/physiologyExon0302 clinical medicineGenes ReporterTranscriptional regulationTrans-Activation (Genetics)/genetics/*physiologyMESH : Tenebrio/geneticsLuciferasesPromoter Regions GeneticTenebrioPeptide sequenceMESH : Metamorphosis Biological/geneticsComputingMilieux_MISCELLANEOUS0303 health sciencesMESH : Amino Acid SequenceMetamorphosis BiologicalMESH : Luciferases/metabolismEcdysone/metabolism/pharmacology3. Good healthInsect ProteinsMESH : TransfectionSequence AnalysisSignal peptideTranscriptional ActivationEcdysoneanimal structuresSequence analysisMolecular Sequence DataMESH : Transcriptional Activation/physiologyReporter/physiologyBiological/genetics/*physiologyMESH : Insect Proteins/physiologyBiologyLuciferases/metabolismTransfectionTenebrio/*genetics/physiologyMESH : Ecdysone/pharmacology03 medical and health sciencesGeneticsAnimalsAmino Acid Sequence[ SDV.BDD ] Life Sciences [q-bio]/Development BiologyMolecular BiologyGeneMESH : Introns/physiology030304 developmental biologyGene LibraryMESH : Metamorphosis Biological/physiologyReporter gene[SDV.GEN.GPO]Life Sciences [q-bio]/Genetics/Populations and Evolution [q-bio.PE]Base SequenceMetamorphosisIntronIntrons/genetics/physiologyMESH : Ecdysone/metabolismSequence Analysis DNADNAMESH : Gene LibraryMolecular biologyIntronsGenesMESH : Tenebrio/physiologyEpidermis/metabolism Gene LibraryInsect ScienceMESH : Insect Proteins/geneticsMESH : Epidermis/metabolismMESH : Base SequenceMESH : AnimalsEpidermisMESH : Promoter Regions Genetic/drug effects[SDE.BE]Environmental Sciences/Biodiversity and EcologyInsect Proteins/*genetics/*physiology030217 neurology & neurosurgeryEpidermis/metabolismMESH : Promoter Regions Genetic/physiologyMESH : Sequence Analysis DNA
researchProduct

Temporally precise control of single-neuron spiking by juxtacellular nanostimulation

2017

Temporal patterns of action potentials influence a variety of activity-dependent intra- and intercellular processes and play an important role in theories of neural coding. Elucidating the mechanisms underlying these phenomena requires imposing spike trains with precisely defined patterns, but this has been challenging due to the limitations of existing stimulation techniques. Here we present a new nanostimulation method providing control over the action potential output of individual cortical neurons. Spikes are elicited through the juxtacellular application of short-duration fluctuating currents (“kurzpulses”), allowing for the sub-millisecond precise and reproducible induction of arbitr…

Male0301 basic medicine2-amino-5-phosphopentanoic acidPatch-Clamp TechniquesTime FactorsPhysiologyComputer scienceAction Potentialsgenetics [Luminescent Proteins]pharmacology [Valine]metabolism [Cytoskeletal Proteins]Mice0302 clinical medicineCortex (anatomy)physiology [Action Potentials]genetics [Nerve Tissue Proteins]6-Cyano-7-nitroquinoxaline-23-dioneNeuronsGeneral Neurosciencepharmacology [Excitatory Amino Acid Antagonists]Valinephysiology [Neurons]medicine.anatomical_structurepharmacology [6-Cyano-7-nitroquinoxaline-23-dione]FemaleSpike (software development)Neuroinformaticsgenetics [Synapsins]Models NeurologicalBiophysicsMice TransgenicNerve Tissue ProteinsOptogenetics03 medical and health sciencesmedicinedrug effects [Neurons]Animalsmetabolism [Synapsins]ddc:610metabolism [Luminescent Proteins]activity regulated cytoskeletal-associated proteingenetics [Cytoskeletal Proteins]analogs & derivatives [Valine]metabolism [Nerve Tissue Proteins]drug effects [Action Potentials]Somatosensory CortexSynapsinsElectric StimulationOptogeneticsCytoskeletal ProteinsLuminescent Proteins030104 developmental biologynervous systemInnovative Methodologycytology [Somatosensory Cortex]NeuronWhole cellExcitatory Amino Acid AntagonistsNeuroscience030217 neurology & neurosurgeryJournal of Neurophysiology
researchProduct

Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study

2018

Background: Among rate-control or rhythm-control strategies, there is conflicting evidence as to which is the best management approach for non-valvular atrial fibrillation (AF) in elderly patients. Design: We performed an ancillary analysis from the ‘Registro Politerapie SIMI’ study, enrolling elderly inpatients from internal medicine and geriatric wards. Methods: We considered patients enrolled from 2008 to 2014 with an AF diagnosis at admission, treated with a rate-control-only or rhythm-control-only strategy. Results: Among 1114 patients, 241 (21.6%) were managed with observation only and 122 (11%) were managed with both the rate- and rhythm-control approaches. Of the remaining 751 patie…

MaleAnti-Arrhythmia Agents/therapeutic useantiarrhythmic agentComorbidityAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; Prevalence; Geriatrics and Gerontology; Pharmacology (medical)030204 cardiovascular system & hematologyanticoagulant agentDiabetes Mellitus/drug therapy0302 clinical medicineHeart RateAtrial Fibrillation80 and overOdds RatioPrevalencePharmacology (medical)030212 general & internal medicineLS4_4Aged 80 and overantiarrhythmic agent anticoagulant agent antithrombocytic agent calcium channel blocking agent digoxinHeart Rate/drug effectsDiabetes MellituAtrial fibrillationantithrombocytic agentdigoxinHospitalizationAnti-Arrhythmia AgentFemaleAnti-Arrhythmia AgentsHumanmedicine.medical_specialtySocio-culturale-Geriatrics and Gerontology; Pharmacology (medical)03 medical and health sciencesInternal medicineDiabetes mellitusHeart rateantiarrhythmic agent; anticoagulant agent; antithrombocytic agent; calcium channel blocking agent; digoxinmedicineDiabetes MellitusHumansAgedPolypharmacyHeart Failurebusiness.industryAtrial Fibrillation/drug therapyOdds ratiomedicine.diseaseHeart Failure/drug therapyComorbidityConfidence intervalcalcium channel blocking agentHeart failurePolypharmacyAged; Aged 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Comorbidity; Diabetes Mellitus; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Male; Odds Ratio; Polypharmacy; PrevalenceGeriatrics and Gerontologybusiness
researchProduct

miR-20b and miR-451a Are Involved in Gastric Carcinogenesis through the PI3K/AKT/mTOR Signaling Pathway: Data from Gastric Cancer Patients, Cell Line…

2020

Gastric cancer (GC) is one of the most common and lethal gastrointestinal malignancies worldwide. Many studies have shown that development of GC and other malignancies is mainly driven by alterations of cellular signaling pathways. MicroRNAs (miRNAs) are small noncoding molecules that function as tumor-suppressors or oncogenes, playing an essential role in a variety of fundamental biological processes. In order to understand the functional relevance of miRNA dysregulation, studies analyzing their target genes are of major importance. Here, we chose to analyze two miRNAs, miR-20b and miR-451a, shown to be deregulated in many different malignancies, including GC. Deregulated expression of miR…

MaleCell signalingAntagonists & inhibitorsCaveolin 1ApoptosisCatalysisTuberous Sclerosis Complex 1 ProteinArticleInorganic Chemistrylcsh:ChemistryMicePhosphatidylinositol 3-KinasesStomach NeoplasmsCell Line TumormicroRNAPTENAnimalsHumans616.33-006.6 [udc]Physical and Theoretical ChemistryMolecular BiologyProtein kinase Blcsh:QH301-705.5SpectroscopyPI3K/AKT/mTOR pathwaybiologyTOR Serine-Threonine Kinasesgastric cancerOrganic ChemistryPTEN PhosphohydrolaseAntagomirsGeneral MedicineStomach neoplasms ; genetics ; MicroRNAs ; genetics ; Phosphoinositide-3 Kinase Inhibitors ; Phosphatidylinositol 3-Kinase ; metabolism ; Proto-Oncogene Proteins c-akt ; antagonists&inhibitors ; Proto-Oncogene Proteins c-akt ; metabolism ; TOR Serine-Threonine Kinases ; antagonists&inhibitors ; TOR Serine-Threonine Kinases ; metabolism ; Signal transduction ; drug effects ; Disease models animal ; MicemiR-451aComputer Science ApplicationsmicroRNAsDisease Models Animallcsh:Biology (General)lcsh:QD1-999biology.proteinCancer researchFemalemiR-20bSignal transductionCarrier ProteinsProto-Oncogene Proteins c-aktTXNIPSignal TransductionPI3K/AKT/mTOR signaling pathwayInternational Journal of Molecular Sciences
researchProduct

Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in …

2013

International audience; We evaluated the impact of cytomegalovirus (CMV)-induced immune responses, autoimmune-induced immune responses, and microbial translocation on immune activation in 191 human immunodeficiency virus type 1-infected patients from the ANRS CO3 Aquitaine Cohort. All enrolled subjects had achieved long-term virological suppression during receipt of combination antiretroviral therapy (cART). HLA-DR(+)/CD38(+) expression was 16.8% among CD8(+) T cells. Independent of age, CD4(+) T-cell count, 16S ribosomal DNA load, and regulatory T-cell count, positive results of Quantiferon CMV analysis (P = .02), positive results of CMV-pp65 enzyme-linked immunosorbent spot analysis (P = …

MaleCytomegalovirusAutoimmunityHIV InfectionsCD8-Positive T-LymphocytesCD38Lymphocyte Activationmedicine.disease_causeAutoimmunityCohort Studies0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyAntiretroviral Therapy Highly ActiveImmunology and Allergy030212 general & internal medicineMESH: Cytomegalovirus Infections/immunologyMESH: HLA-DR Antigens/metabolismMESH: Cohort Studies0303 health sciencesMESH: HIV Infections/drug therapyvirus diseasesViral Load3. Good healthInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyMESH: CD8-Positive T-Lymphocytes/immunologyCytomegalovirus Infections[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleFranceMESH: Cytomegalovirus/immunologyMESH: Viral Load[SDV.IMM] Life Sciences [q-bio]/ImmunologyCongenital cytomegalovirus infectionHuman leukocyte antigenBiologyQuantiFERONViral Matrix Proteins03 medical and health sciencesImmune systemMESH: Cross-Sectional StudiesAntigenMESH: AutoimmunitymedicineHumansMESH: Phosphoproteins/immunology[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyMESH: Viral Matrix Proteins/immunology030304 developmental biologyMESH: HumansMESH: HIV-1/geneticsMESH: HIV-1/physiologyMESH: HIV Infections/immunologyHLA-DR AntigensPhosphoproteinsmedicine.diseaseVirologyMESH: MaleMESH: Lymphocyte Activation/immunologyMESH: FranceCross-Sectional Studies[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieImmunologyHIV-1[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieMESH: HIV-1/drug effectsMESH: FemaleCD8
researchProduct

Patterns of transmitted HIV drug resistance in Europe vary by risk group

2014

BACKGROUND: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. METHODS: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. RESULTS: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM…

MaleEpidemiologygenotypeHuman immunodeficiency virus 1HIV InfectionsRNA directed DNA polymerase inhibitorhigh risk patientLogistic regressionSettore MED/42 - Igiene Generale E ApplicataMen who have sex with men0302 clinical medicineImmunodeficiency Virusesmiddle agedstatistics and numerical data10. No inequalitySubstance Abuse Intravenous0303 health sciencesadulttransmissionvirus diseasesvirus transmissionhighly active antiretroviral therapyHIV immunopathogenesis3. Good healthMedical MicrobiologyViral Pathogenshigh risk behaviorMedicineScience & Technology - Other TopicsPOPULATIONShealth programanti human immunodeficiency virus agentUSERSmedicine.medical_specialtyScienceSexual BehaviorImmunologySexually Transmitted Diseasesintravenous drug abuse-Microbiology03 medical and health sciencesAntibiotic resistanceSDG 3 - Good Health and Well-beingHuman immunodeficiency virus infectionproteinase inhibitorHumansProtease InhibitorshumanHeterosexualityMicrobial PathogensseroconversionMedicine and health sciencesScience & TechnologyGenitourinary InfectionsMUTATIONSVirologymajor clinical studyLogistic Modelstransmitted drug resistance mutationHeterosexualityHIV-1Viral Diseases:Medical sciences: 700::Basic medical dental and veterinary sciences: 710::Medical immunology: 716 [VDP]drug responsemen who have sex with menDrug resistanceClinical immunologygeographyAPPEARANCEmale homosexualityMedizinische Fakultätimmune system diseasesEpidemiologyINFECTIONMedicine and Health Sciencessubstance abuse030212 general & internal medicineriskMultidisciplinaryACTIVE ANTIRETROVIRAL THERAPYTransmission (medicine)virus mutationQRarticleObstetrics and GynecologyHIV diagnosis and managementMiddle AgedvirologyMultidisciplinary SciencesEuropeInfectious Diseasesfemale:Medisinske fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716 [VDP]Reverse Transcriptase InhibitorsHIV clinical manifestationsFemaleepidemiologyblood samplingHIV drug resistanceResearch ArticleAdultRiskrisk-groupAnti-HIV AgentsUrologyprevalenceInfectious Disease Epidemiologysexual behaviorRisk-Takingmaleantiviral resistanceInternal medicineDrug Resistance Viralmedicinecontrolled studyddc:610Homosexuality Male030304 developmental biologydrug resistanceBiology and life sciencesbusiness.industrystatistical modelHIVCD4 lymphocyte countheterosexualitynonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionDiagnostic medicineINDIVIDUALSdrug effectsWomen's Healthbusinesstrend study
researchProduct

No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy

2011

An investigation was undertaken to determine whether specific pol mutations hinder long-term immune recovery regardless of virological response. In total, 826 patients with >50 HIV RNA copies/ml, who underwent genotypic resistance testing between 1 January 2000 and 31 December 2003 after >3 years of antiretroviral treatment, and were followed up for >3 years after genotypic resistance testing, were analyzed retrospectively. The outcome of the study was the lack of immune recovery after >3 years of follow-up, defined as a slope by linear regression 50 copies/ml divided by the number of HIV RNA measurements during follow-up. Logistic regression was used for univariable and multivariable analy…

MaleHIV InfectionsDrug resistanceLogistic regressionResistance to nucleoside reverse transcriptase inhibitorCD4+ T-lymphocyteRetrospective StudieImmunopathologyAntiretroviral Therapy Highly ActiveResistance to non-nucleoside reverse transcriptase inhibitorgeneticsResistance to protease inhibitorHIV Infectionresistance to nucleoside reverse transcriptase inhibitorsViralSidaresistance to protease inhibitorsbiologyReverse-transcriptase inhibitorViral LoadGenes poldrug therapy/immunology/virologyReverse Transcriptase InhibitorInfectious DiseasesTreatment Outcomeresistance to non-nucleoside reverse transcriptase inhibitorsReverse Transcriptase InhibitorsFemaleViral loadmedicine.drugHumanpolAnti-HIV AgentsAntiretroviral TherapyViremiaInfectious DiseaseSettore MED/17 - MALATTIE INFETTIVEpharmacology/therapeutic useAcquired immunodeficiency syndrome (AIDS)VirologyDrug Resistance ViralmedicineHumansHighly ActiveRetrospective StudiesAnti-HIV Agents; pharmacology/therapeutic use Antiretroviral Therapy; Highly Active CD4 Lymphocyte Count Drug Resistance; Viral; genetics Female Genes; pol HIV Infections; drug therapy/immunology/virology HIV-1; drug effects/enzymology/genetics Humans Male Mutation Retrospective Studies Reverse Transcriptase Inhibitors; therapeutic use Treatment Outcome Viral Loaddrug resistanceAnti-HIV Agentbiology.organism_classificationmedicine.diseaseVirologyCD4 Lymphocyte CountGenesdrug effects/enzymology/geneticstherapeutic useMutationCD4+ T-lymphocytesHIV-1
researchProduct

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

The role of cuticular pheromones in courtship conditioning of Drosophila males

2005

1072-0502 (Print) Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.; Courtship conditioning is an associative learning paradigm in Drosophila melanogaster, wherein male courtship behavior is modified by experience with unreceptive, previously mated females. While the training experience with mated females involves multiple sensory and behavioral interactions, we hypothesized that female cuticular hydrocarbons function as a specific chemosensory conditioned stimulus in this learning paradigm. The effects of training with mated females were determined in courtship tests with either wild-type virgin females as courtship targets, or with…

MaleInsect Proteins/physiologyPheromones/pharmacology/*physiologyAlkenes/*pharmacologyCognitive Neurosciencemedia_common.quotation_subjectSexual BehaviorConditioning ClassicalZoologyAlkenesPheromonesCourtshipCellular and Molecular NeuroscienceSexual Behavior AnimalDrosophilidaeAnimalsChemoreceptors/physiologyDrosophila melanogaster/*physiologyreproductive and urinary physiologymedia_commonAssociation Learning/drug effects/physiologyCommunicationbiologyCourtship displaybusiness.industryfungiCourtshipClassical conditioningAssociation Learningbiology.organism_classificationResearch PapersChemoreceptor CellsAssociative learningNeuropsychology and Physiological PsychologyDrosophila melanogasterSex pheromonebehavior and behavior mechanismsPheromoneInsect ProteinsFemaleAnimal/drug effects/*physiologyDrosophila melanogasterbusinessClassical/drug effects/*physiologyConditioning
researchProduct